[efficacy, pharmacokinetics, and safety of icatibant for the treatment of japanese patients with an acute attack of hereditary angioedema: a phase 3 open-label study].
CONCLUSION: Although our study was limited by the small number of patients, we found that icatibant was an effective and well-tolerated treatment for Japanese patients with acute HAE attacks, regardless of whether it was administered by a HCP or self-administered.
PMID: 29553114 [PubMed - in process]
Source: Allergology International - Category: Allergy & Immunology Tags: Arerugi Source Type: research
More News: Gastroenterology | Headache | Japan Health | Migraine | Respiratory Medicine | Skin | Study